News & Updates

12-year review of HK Breast Cancer Registry: Neoadjuvant chemo effective in stage ≥II, HER2-positive and triple-negative dise
12-year review of HK Breast Cancer Registry: Neoadjuvant chemo effective in stage ≥II, HER2-positive and triple-negative disease
26 May 2023 byNatalia Reoutova

A 12-year review of Hong Kong Breast Cancer Registry (HKBCR) records of patients diagnosed with breast cancer in 2006–2017 showed that neoadjuvant chemotherapy (NAC) was effective in tumour downstaging, with one-fifth of patients subsequently achieving pathological complete response (pCR) in the breast and axillary lymph nodes. Patients with HER2-positive (nonluminal) and triple-negative disease were most likely to achieve pCR.

12-year review of HK Breast Cancer Registry: Neoadjuvant chemo effective in stage ≥II, HER2-positive and triple-negative disease
26 May 2023
Serum osteopontin levels predicts response to treatment in unresectable HCC
Serum osteopontin levels predicts response to treatment in unresectable HCC
25 May 2023

Among patients with unresectable hepatocellular carcinoma (HCC) scheduled to receive standard combination therapy with atezolizumab plus bevacizumab, those with high levels of serum osteopontin at baseline are likely to have poor response to treatment, as shown in a study.

Serum osteopontin levels predicts response to treatment in unresectable HCC
25 May 2023
Paediatric TB care riddled with uncertainty, study says
Paediatric TB care riddled with uncertainty, study says
25 May 2023 byJairia Dela Cruz

Uncertainty weighs heavily on managing tuberculosis (TB) infection in children, with multi-level factors influencing the decision-making regarding testing and treatment.

Paediatric TB care riddled with uncertainty, study says
25 May 2023
Nonsmoking, asbestos-exposed people still at risk of lung cancer
Nonsmoking, asbestos-exposed people still at risk of lung cancer
25 May 2023
Sofosbuvir/velpatasvir effective, safe for paediatric HCV
Sofosbuvir/velpatasvir effective, safe for paediatric HCV
25 May 2023
2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains
2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains
25 May 2023 byJairia Dela Cruz

Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.

2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains
25 May 2023